October 01, 2018

New EAS FHSC publication - a global heatmap of FH


Overview of the current status of Familial Hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

FHSC’s new publication “Overview of the current status of Familial Hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)” was accepted for publication on Atherosclerosis at the beginning of September and is now published, full text available for free.

The overview FHSC report heads a special issue section of the October issue of the Journal, which also includes a thematic series of 41 peer-assessed articles on diverse aspects of the care of FH. Including 5 invited reviews from leading experts in the field, this special issue section uniquely provides an extensive survey of the current status of FH patient management in over 60 contributing countries worldwide – allowing international comparisons, and highlighting gaps in knowledge, variations from one region/country to another, and initiatives currently ongoing related to FH patient care.

Thanks to all FHSC contributors for participating in this collaboration.

To the publication >>
To the Commentary by Jane Stock >>

 

FH Week follow-up

We also thank all followers of #FHWeek for sharing and tweeting information and experiences on FH during FH Week 2018. If you missed out on something - all newsletters are available online.

 


To FH Week 2018 main page >>
To Newsletters and social media >>
To list of FH events >>

Editorial on "Cholesterol and inflammatory risk: insights from secondary and primary prevention"

EAS Scientific writer Jane Stock, regularly comments and summarises selected articles in the Society's journal Atherosclersosis.

Low-density lipoprotein cholesterol is indisputably causal for cardiovascular disease, and a major modifiable risk factor. Results from the CANTOS trial also indicate the relevance of inflammatory risk. Both types of risk are important in secondary and primary prevention settings, as discussed in this commentary.

To the commentary by Jane Stock>>

EAS ACADEMY

OPEN LECTURE SEPTEMBER - OCTOBER

Open Lectures are a new initiative from the Society to highlight our online educational platform EAS ACADEMY. Every other month we select one interesting lecture from a recent course or Congress and make it available for free, to members and non-members.

 


Imaging and CVD risk estimation (population studies) is the topic for the Open Lecture for September - October on EAS Academy. The video presentation by Professor Valentin Fuster was recorded during the 86th EAS Congress in Lisbon in May.

Free access to the lecture will be open until October 31.

To the Open Lecture >>
How to register as EAS member >>

THEMED SHORT TRACK: New and emerging therapies to treat dyslipidaemias and atherosclerosis

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s SHORT TRACK topic is New and emerging therapies to treat dyslipidaemias and atherosclerosis. Despite the significant progress in therapies used to treat dyslipidemias in the daily clinical practice, there is still the need of new therapies to efficiently treat atherosclerosis and to further reduce the incidence of cardiovascular disease.

 


PCSK9 Inhibition in high risk patients
This presentation is made by Dr. Gabriel Steg, Professor of Cardiology at the UniversityParis-Diderot, and Director of the Coronary Care Unit of Bichat Hospital,Paris, France.

To the presentation >>

Anti-Inflammatory Therapy for Atherosclerosis - Theory and Practice

Professor Peter Libby, world-wide recognized specialist in vascular biology, atherosclerosis and preventive cardiology at Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine at Harvard Medical School.

To the presentation >>

  Silencing genes, new targets

Professor Sotirios Tsimikas, Director of Vascular Medicine and Professor of Medicine,University of California San Diego, La Jolla, USA.

To the presentation >>

 

These presentations are open for EAS members only.

How to register as an EAS member >>

 

EAS ADVANCED COURSES 2018

Open for application:
Advanced Courses in Rare Lipid Disorders

EAS is pleased to announce the Society's endorsement of Advanced Courses on the topic of Rare Lipid Disorders. These four, stand-alone, 1-day courses will take place autumn 2018 in Barcelona, Spain (September); Milan, Italy (October); Berlin Germany (October) and Lyon, France (November); The majority of the lectures will be given in the respective national language.

The aim of the courses is to examine rare genetic disorders of lipid metabolism including ß-sitosterolemia; cerebrotendinous xanthomatosis, lysosomal acid lipase deficiency, disorders of high density lipoprotein and familial hypocholesterolemias. While the prevalence of these individual disorders is low, collectively they are important and the busy specialized practitioner will encounter patients with these conditions. Lipidologists need to be familiar with their diagnosis and treatment as they may be associated with high morbidity and mortality.

The objective of the courses is to review practical aspects of evaluation and management, and to describe real clinical cases of these disorders.

Read more and apply >>



Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)

Visit: eas-society.org

About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS, either through membership, attending an EAS event, or registering to one of the Society’s educational activities.

  

European Atherosclerosis Society
Mässans Gata 10
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@

 

European Atherosclerosis Society © 2018